Experimental Therapeutics

实验治疗学

基本信息

批准号：
10395520
负责人：
Aliasger K Salem
金额：
$ 3.39万
依托单位：
UNIVERSITY OF IOWA
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
起止时间：
2000-07-14 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10395520
关键词：
Achievement Agonist Basic Science Budgets Cancer Center Support Grant Chemotherapy and/or radiation Clinical Clinical Investigator Clinical Research Clinical Trials Collaborations Comprehensive Cancer Center DNA Repair Development Direct Costs Endometrial Carcinoma Ewings sarcoma Funding Funding Mechanisms Goals Institution Investigational Therapies Journals Laboratories Malignant Neoplasms Manuscripts Molecular Target Monitor Multiple Myeloma Peer Review Pharmacologic Ascorbate Phase Phenotype Private Sector Publications Radiation therapy Research Research Personnel Research Project Grants Scientist Testing Therapeutic Toll-like receptors Toxic effect Toxicity due to chemotherapy Translating Translational Research base bench to bedside cancer cell cancer immunotherapy college drug development high throughput screening innovation member nanoparticle new therapeutic target novel novel therapeutic intervention preclinical evaluation programs response translational cancer research translational scientist

项目摘要

PROJECT SUMMARY/ABSTRACT Research in the Experimental Therapeutics (ET) program focuses on identification, development and testing of new cancer therapeutics. This is accomplished through three overlapping specific aims centered on 1) identifying potential targets and discovering therapeutics leads, 2) conducting preclinical evaluation of promising new therapeutic approaches, and 3) evaluating innovative and promising agents, combinations, and approaches to monitoring response in clinical trials. ET investigators are highly collaborative. Key scientific achievements of ET investigators over the prior funding period include identification of novel therapeutic targets in endometrial cancer and myeloma, nanoparticle based drug development, cancer immunotherapy based on toll-like receptor (TLR9) agonists, use of pharmacologic ascorbate to enhance the efficacy and reduce the toxicity of both chemotherapy and radiation therapy (in collaboration with the FRMI Program), and expansion of investigator-initiated and Phase I capabilities including trials of intralesional therapy. There are 28 full and 16 associate members of ET including laboratory-based, translational and clinical investigators spanning 13 departments across five colleges. Annual total peer-reviewed cancer direct costs in the most recent budget year was $2.7 million ($1.9 million from the NCI). Additional funding included $3.8 million for non-peer-reviewed research projects. ET members are highly collaborative having authored or co-authored 291 cancer-related peer-reviewed publications in the past five years, with 24% (n= 69) intraprogrammatic, 43% (n= 124) interprogrammatic, and 42% (n= 123) interinstitutional publications. Twenty-nine manuscripts appeared in high impact journals (Impact Factor ≥10).

项目摘要/摘要实验疗法（ET）计划的研究重点是识别，开发和测试新的癌症治疗。这是通过以1为中心的三个重叠特定目标来完成的确定潜在靶标和发现疗法铅，2）进行临床前评估有希望的新治疗方法，以及3）评估创新和有前途的药物，组合和在临床试验中监测反应的方法。 ET研究人员是高度协作的。关键科学 ET研究人员在上一期资金期间的成就包括鉴定新疗法子宫内膜癌和骨髓瘤的靶标，基于纳米颗粒的药物发育，癌症免疫疗法基于Toll样受体（TLR9）激动剂，使用药物抗坏血酸来提高效率和降低化学疗法和放射疗法的毒性（与FRMI计划合作），以及扩展研究者发射和I期能力，包括病房疗法的试验。有28 ET的全部和16名员工，包括基于实验室的，翻译和临床研究人员跨越了五所大学的13个系。最多的年度同行评审癌症直接成本最近的预算年度为270万美元（NCI的190万美元）。额外的资金包括380万美元未经审查的研究项目。 ET成员在撰写或共同撰写过高度协作 291与癌症相关的同行评审出版物在过去五年中，有24％（n = 69），43％（n = 124）解释性截图，42％（n = 123）机构出版物。二十九个手稿出现在高影响期刊中（影响因子≥10）。